#1 Clinical Trials Search in Europe

Valbenazine Ditosylate

Valbenazine Ditosylate, a promising drug candidate, is currently being studied in clinical trials for its potential in treating various neurological and psychiatric conditions. These trials aim to evaluate the efficacy, safety, and tolerability of Valbenazine as an adjunctive treatment for schizophrenia and as a potential therapy for dyskinesia due to cerebral palsy. The ongoing research seeks to address unmet medical needs and improve the quality of life for patients with these challenging disorders.

Table of Contents

What is Valbenazine?

Valbenazine Ditosylate, also known as Valbenazine Tosylate or simply Valbenazine, is a medication being studied for its potential to treat certain movement disorders[1]. It is developed by Neurocrine Biosciences Inc. and is currently undergoing clinical trials to evaluate its effectiveness and safety[2].

How Does It Work?

Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is a protein in the brain that helps package and transport certain chemicals (neurotransmitters) between brain cells. By inhibiting VMAT2, Valbenazine can help regulate the levels of these neurotransmitters, which may help control involuntary movements associated with certain disorders[1].

What Conditions Does Valbenazine Treat?

Based on the ongoing clinical trials, Valbenazine is being studied for its potential to treat:

  • Schizophrenia: Specifically, it’s being tested as an adjunctive (add-on) treatment for people with schizophrenia who have inadequate response to antipsychotic treatment[1].
  • Dyskinesia due to Cerebral Palsy (DCP): This includes choreiform movements, which are irregular, unpredictable, dance-like movements[2].

It’s important to note that while these conditions are the focus of current studies, Valbenazine is not yet approved for treating these disorders. The clinical trials aim to determine its effectiveness and safety for these uses.

How is Valbenazine Administered?

Valbenazine is being tested in the form of oral capsules. In the clinical trials, it’s being administered once daily. The dosage varies depending on the study and condition being treated, ranging from 30 mg to 80 mg per day[1][2].

Current Clinical Trials

There are currently two Phase 3 clinical trials studying Valbenazine:

  1. Study for Schizophrenia: This trial is evaluating Valbenazine as an adjunctive treatment for people with schizophrenia who don’t respond adequately to antipsychotic treatment. The main goal is to see if Valbenazine can improve schizophrenia symptoms compared to a placebo[1].

  2. Study for Dyskinesia due to Cerebral Palsy: This trial is testing Valbenazine in both children and adults with dyskinesia (abnormal movements) caused by cerebral palsy. The primary aim is to see if Valbenazine can improve chorea (a type of involuntary movement) in these patients[2].

Both studies are randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either Valbenazine or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.

Potential Side Effects and Precautions

As Valbenazine is still in clinical trials, its full side effect profile is not yet known. However, based on the exclusion criteria in the studies, some precautions are being taken for people with:

  • History of long QT syndrome or cardiac arrhythmia
  • Moderate or severe liver problems
  • History of neuroleptic malignant syndrome
  • Substance use disorders
  • Suicidal thoughts or behaviors

It’s important to remember that these are precautionary measures for the clinical trials and don’t necessarily reflect confirmed side effects or contraindications[1][2].

As with any medication, if Valbenazine becomes approved for use, it will be crucial to discuss potential risks and benefits with a healthcare provider before starting treatment.

Aspect Details
Drug Name Valbenazine Ditosylate
Conditions Studied Schizophrenia, Dyskinesia due to cerebral palsy
Trial Phases Phase 3
Administration Oral capsules
Primary Objectives Evaluate efficacy, safety, and tolerability
Key Measures PANSS scores, CGI-S scores, TMC scores, PSP scores
Patient Groups Adults with schizophrenia or dyskinesia due to cerebral palsy
Study Design Randomized, double-blind, placebo-controlled

FAQ

  • What is Valbenazine Ditosylate? Valbenazine Ditosylate is a drug being studied for its potential to treat neurological and psychiatric disorders. It is a vesicular monoamine transporter 2 (VMAT2) inhibitor, which means it affects certain chemical processes in the brain.
  • What conditions are being studied in these clinical trials? The clinical trials are focusing on two main conditions: schizophrenia (as an adjunctive treatment for patients not responding well to current antipsychotic medications) and dyskinesia due to cerebral palsy (a movement disorder causing involuntary muscle movements).
  • How is Valbenazine administered in these trials? Valbenazine is administered orally in the form of capsules. The dosage and frequency may vary depending on the specific trial and condition being studied.
  • What are the main goals of these clinical trials? The main goals are to evaluate the efficacy (how well the drug works), safety, and tolerability of Valbenazine. Researchers are looking at how it affects symptoms, overall functioning, and quality of life for patients with schizophrenia or dyskinesia due to cerebral palsy.
  • Who can participate in these clinical trials? Eligibility varies by trial, but generally includes adults diagnosed with schizophrenia or dyskinesia due to cerebral palsy. There are specific inclusion and exclusion criteria, such as stable medical conditions, no recent substance abuse, and meeting certain symptom severity thresholds.

Ongoing Clinical Trials on Valbenazine Ditosylate

  • Study on Valbenazine for Patients with Schizophrenia Not Responding Well to Antipsychotic Treatment

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Romania Slovakia Spain

  • Study on Valbenazine for Treating Dyskinesia in Children and Adults with Cerebral Palsy

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Poland Portugal Spain

  • Study on Valbenazine for Patients with Schizophrenia Not Responding Well to Antipsychotic Treatment

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Italy Romania Slovakia Spain

Glossary

  • Adjunctive treatment: A therapy used in addition to the primary or initial treatment to maximize its effectiveness.
  • Antipsychotic: A type of medication used to manage symptoms of psychotic disorders, particularly schizophrenia.
  • Cerebral palsy: A group of disorders affecting movement and muscle tone or posture, caused by damage to the developing brain, most often before birth.
  • Clinical trial: A research study that tests how well new medical approaches work in people.
  • Dyskinesia: Abnormal, uncontrollable, involuntary movements, often a side effect of long-term use of certain medications.
  • Efficacy: The ability of a drug or treatment to produce the desired effect.
  • Placebo: An inactive substance that looks like the drug being tested, used as a control in clinical trials.
  • Schizophrenia: A chronic and severe mental disorder that affects how a person thinks, feels, and behaves.
  • Tolerability: The degree to which side effects of a drug can be tolerated by a patient.
  • VMAT2 inhibitor: A type of medication that blocks the action of vesicular monoamine transporter 2, affecting the levels of certain chemicals in the brain.

References

  1. http://clinicaltrials.eu/trial/study-on-valbenazine-for-patients-with-schizophrenia-not-responding-well-to-antipsychotic-treatment/
  2. http://clinicaltrials.eu/trial/study-on-valbenazine-for-treating-dyskinesia-in-children-and-adults-with-cerebral-palsy/